- Home
- TKNO vs CMRX Comparison
TKNO vs CMRX Comparison
Compare TKNO & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKNO
- CMRX
- Stock Information
- Founded
- TKNO 1996
- CMRX 2000
- Country
- TKNO United States
- CMRX United States
- Employees
- TKNO N/A
- CMRX N/A
- Industry
- TKNO Medicinal Chemicals and Botanical Products
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- TKNO Health Care
- CMRX Health Care
- Exchange
- TKNO Nasdaq
- CMRX Nasdaq
- Market Cap
- TKNO 430.2M
- CMRX 394.1M
- IPO Year
- TKNO 2021
- CMRX 2013
- Fundamental
- Price
- TKNO $7.45
- CMRX $5.15
- Analyst Decision
- TKNO Buy
- CMRX Strong Buy
- Analyst Count
- TKNO 2
- CMRX 2
- Target Price
- TKNO $5.00
- CMRX $8.50
- AVG Volume (30 Days)
- TKNO 266.7K
- CMRX 1.7M
- Earning Date
- TKNO 03-04-2025
- CMRX 03-07-2025
- Dividend Yield
- TKNO N/A
- CMRX N/A
- EPS Growth
- TKNO N/A
- CMRX N/A
- EPS
- TKNO N/A
- CMRX N/A
- Revenue
- TKNO $36,347,000.00
- CMRX $159,000.00
- Revenue This Year
- TKNO $3.47
- CMRX N/A
- Revenue Next Year
- TKNO $12.07
- CMRX $1,690.28
- P/E Ratio
- TKNO N/A
- CMRX N/A
- Revenue Growth
- TKNO N/A
- CMRX N/A
- 52 Week Low
- TKNO $1.16
- CMRX $0.75
- 52 Week High
- TKNO $10.37
- CMRX $5.53
- Technical
- Relative Strength Index (RSI)
- TKNO 38.57
- CMRX 76.25
- Support Level
- TKNO $7.76
- CMRX $3.94
- Resistance Level
- TKNO $8.45
- CMRX $5.53
- Average True Range (ATR)
- TKNO 0.62
- CMRX 0.30
- MACD
- TKNO -0.19
- CMRX 0.07
- Stochastic Oscillator
- TKNO 0.00
- CMRX 78.29
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. It derives maximum revenue from United States.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.